Basit öğe kaydını göster

dc.contributor.authorZuhur, Ferit
dc.contributor.authorMusellim, Benan
dc.contributor.authorZuhur, Sayid Shaw
dc.contributor.authorOngen, Gul
dc.contributor.authorZuhur, Cigdem
dc.date.accessioned2021-03-03T11:17:05Z
dc.date.available2021-03-03T11:17:05Z
dc.date.issued2012
dc.identifier.citationZuhur F., Zuhur S. S. , Zuhur C., Musellim B., Ongen G., "Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey", RHEUMATOLOGY INTERNATIONAL, cilt.32, sa.6, ss.1655-1661, 2012
dc.identifier.issn0172-8172
dc.identifier.othervv_1032021
dc.identifier.otherav_26f90647-9a3d-4f99-91cb-5cd10def3900
dc.identifier.urihttp://hdl.handle.net/20.500.12627/31082
dc.identifier.urihttps://doi.org/10.1007/s00296-011-1842-x
dc.description.abstractThe objective of the current study was to determine survival and factors that affect survival in progressive systemic sclerosis (SSc) with pulmonary involvement. A total of 102 SSc patients with pulmonary involvement, diagnosed between 1994 and 2008, enrolled into the study. Pulmonary involvement was defined based on the presence of interstitial changes on high-resolution CT (HRCT). Demographical, clinical, radiological, and laboratory data of the patients were found from patient records and were used for the evaluation of survival. The mean age of the patients at diagnosis was 50 +/- 12 years. In follow-up, 22 (21.5%) patients were deceased. The mean age of the patients at death was 55 +/- 12 years. Seventy-eight percent of known causes of mortality were related to pulmonary complications. After any initial systemic manifestation of disease, the mean survival was 447 +/- 27 months and 5, 10, 15, and 20 year survival rates were 99, 92, 83, and 72%, respectively. The mean survival after initial pulmonary manifestation was 269 +/- 23 months and 5, 10 and 15 year survival rates were 91, 73 and 57%, respectively. Mean survival was 113 +/- 5 months, and 5- and 10-year survival rates after the lung involvement detected with HRCT were 85 and 66%, respectively. Pulmonary artery hypertension, disease onset after the age of 40, and honeycombing on HRCT were associated with poor survival. Our data suggest that pulmonary involvement is the most important determinant factor for poor prognosis in patients with SSc. Therefore, echocardiography, pulmonary function tests, and HRCT should be performed in early stages of the disease for early diagnosis of pulmonary artery hypertension and lung involvement before irreversible vascular and interstitial changes exist.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleSurvival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey
dc.typeMakale
dc.relation.journalRHEUMATOLOGY INTERNATIONAL
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume32
dc.identifier.issue6
dc.identifier.startpage1655
dc.identifier.endpage1661
dc.contributor.firstauthorID15068


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster